| 0.0006 0 (0%) | 10-27 13:25 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Founded in 1983 and headquartered in Miramar, Florida, Generex Biotechnology Corporation initially specialized in the delivery of large molecule drugs into the oral cavity via a portable aerosol applicator for use in Canada and the United States, notably offering Generex Oral-lyn, an oral insulin product. The company also had a significant focus on oncology, developing AE37, a synthetic peptide vaccine that had completed Phase IIb clinical trials aimed at stimulating a potent and specific immune response against HER-2/neu oncogenes in breast and prostate cancer patients. Beyond therapeutics, Generex was involved in the development, manufacturing, and distribution of rapid point-of-care in-vitro medical diagnostics for a spectrum of infectious diseases, including HIV, tuberculosis, malaria, and hepatitis, providing both test kits and cassettes. Its product portfolio further included Excellagen, a wound-conforming gel. The company's research and development efforts also extended to immunotherapeutic products, additional vaccines, and an extracellular matrix hydrogel solution designed for the treatment of Ulcerative Colitis. In addition, Generex manufactured and sold specialized surgical kits for foot and ankle procedures, containing plates, screws, and tools, and distributed a wide array of surgical supplies, orthopedic implants, artificial joints, biologics, medical devices, and regenerative medicine products. The corporation also acted as the general partner for a Management Services Organization. However, on April 23, 2022, an involuntary petition for Chapter 7 liquidation was filed against Generex Biotechnology Corporation in the U.S. Bankruptcy Court for the Southern District of Florida, which was subsequently approved by the court on June 6, 2022.
Wed, 12 Sep 2018
James Anderson, MD, Joins Know Labs as Medical Director - BioSpace
Sat, 31 Dec 2016
Lilly and Generex to develop buccal form of insulin - Pharmaceutical Online
Mon, 24 Jun 2013
Fox Analyst Charles Payne Was Paid To Push Now Worthless Stocks - Media Matters for America
Tue, 17 May 2005
Oral Insulin Spray (Oral-lyn) for Type 1 and 2 Diabetes in Ecuador - Diabetes In Control
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|